Stem Cell Assurance, Inc.
Stem Cell Assurance, Inc. is listed today as BioRestorative Therapies, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $1 M | Private placement after listing | Under $2 million | equity, options | SEC | |
| Jan 2014 | $14 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Apr 2012 | $2 M | No. 2 | Under $2 million | equity, debt, options | SEC | |
| Nov 2010 | $1 M | No. 1 | Under $2 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company BioRestorative Therapies, Inc., its revenue in fiscal 2025 came from these product and service lines: Royalty $60,000 (17%).
Annual report (SEC XBRL) · Dec 2025
Stem Cell Assurance, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Oct 2025).
SEC Form D (revenue range) · Oct 2025
Revenue range over time, as stated in its notices: no revenue in 2012; revenue of up to $1 million in 2016; revenue of up to $1 million in 2025.
SEC Form D (revenue range) · Oct 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2025
Products and services#
No products or services of Stem Cell Assurance, Inc. are on record.
Investors#
No investor of Stem Cell Assurance, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.
Largest shareholders today
Institutions holding BioRestorative Therapies, Inc. shares, as of Sep 30, 2026.
- Citadel Advisors LLC$0 M—
- Jane Street Group, LLC$0 M—
- HRT Financial LP$0 M—
- Vanguard Fiduciary Trust Co$0 M—
- UBS Group AG$0 M—
- Vanguard Capital Management LLC$0 M—
- Tower Research Capital LLC (TRC)$0 M—
- Osaic Holdings, Inc.$0 M—
- SBI Securities Co., Ltd.$0 M—
- Rossby Financial, LCC$0 M—
- TD Waterhouse Canada Inc.$0 M—
- Citigroup Inc$0 M—
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC$0 M—
- Parallel Advisors, LLC$0 M—
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Francisco Silva | Executive officer | Oct 2025 |
| Lance Alstodt | Executive officer | Oct 2025 |
| Robert Kristal | Executive officer | Oct 2025 |
| Edward L. Field | President, Disc/Spine Division | May 2016 |
| Francisco Jeffrey Silva | Vice President of Research and Development and Assistant Secretary | May 2016 |
| Mandy Jeffrey Clyde | Vice President of Operations and Secretary | May 2016 |
| Mark Weinreb | Chief Executive Officer, Chairman of the Board and President | May 2016 |
| Mandy Clark | Executive officer | Apr 2012 |
| Richard Proodian | Executive officer | Mar 2011 |
| David A Rosa | Director | Oct 2025 |
| Francisco Silva | Director | Oct 2025 |
| Lance Alstodt | Director | Oct 2025 |
| Nickolay V Kukekov | Director | Oct 2025 |
| Patrick F Williams | Director | Oct 2025 |
| A. Jeffrey Radov | Director | May 2016 |
| Charles S. Ryan | Director | May 2016 |
| John M. Desmarais | Director | May 2016 |
| Mark Weinreb | Chief Executive Officer, Chairman of the Board and President | May 2016 |
| Paul Jude Tonna | Director | May 2016 |
| Robert B. Catell | Director | May 2016 |
| Joseph B. Swiader | Director | Jan 2015 |
| Joel San Antonio | Director | Apr 2012 |
| Joseph Ross | Director | Mar 2011 |
| Kurt Wagner | Director | Mar 2011 |
| Mandy Clark | Director | Mar 2011 |
| Richard Proodian | Director | Mar 2011 |
| Gloria Jeffrey McConnell | Promoter | Apr 2012 |
| Tommy Jeffrey Berger | Promoter | Apr 2012 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.